EUVIMEDEUVIMED entdecken
Leitlinie

Cost-effectiveness of new guideline-based management for primary aldosteronism

Yiyang Fu, Yongpeng Xie, Xizi Zhang, Wei Li, Bin Peng, Ying Jing, Jinbo Hu, Qifu Li, Yao Zhang, Shumin Yang

Journal of the Renin-Angiotensin-Aldosterone System · 2026-11 · 27

DOI: 10.1177/14703203261505146 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the Renin-Angiotensin-Aldosterone System, online erschienen am 01.11.2026. Verfasst von Yiyang Fu und 9 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Chongqing Technology Innovation and Application Development Special Key Project, The Role of CMPF in Idiopathic Hyperaldosteronism: Mechanistic and Fundamental Research, Chongqing Outstanding Youth Science Fund project.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The 2025 Endocrine Society Guideline expands PA screening to all patients with hypertension, even on interfering medication, and recommends repeat testing when appropriate, while adopting a more stratified approach to subsequent diagnostic evaluation. Materials and Methods In this simulation, we evaluated two guideline-directed screening and management strategies for PA in a cohort of patients with newly diagnosed hypertension. By developing a decision tree-Markov model and incorporating relevant parameters from epidemiological surveys and literature, we analyzed the cost-effectiveness with Quality-Adjusted Life Years (QALYs) and the incremental cost-effectiveness ratio (ICER). The model's reliability was evaluated through the sensitivity analysis.

Results

Within the Chinese healthcare setting, the updated guideline dominated the original strategy (cost: 3329.77USD vs. 3568.29USD; QALYs: 10.85 vs. 10.82), yielding an ICER of −7950.67USD/QALY. Across multiple scenario analyses, including alternative healthcare-cost settings and higher MRA treatment costs, the updated Guideline remained economically favorable. Sensitivity analyses and model validation further supported the overall stability and plausibility of the findings.

Conclusions

Over a 30-year horizon, management of PA under the updated Guideline is more cost-effective than the original Guideline.

Förderung

  • Chongqing Technology Innovation and Application Development Special Key Project
  • The Role of CMPF in Idiopathic Hyperaldosteronism: Mechanistic and Fundamental Research
  • Chongqing Outstanding Youth Science Fund project
  • The Chongqing Postdoctoral Research Project Special Funding
  • Chongqing medical scientific research project
  • The China Postdoctoral Science Foundation
  • The National Natural Science Foundation of China

Zitieren

APA

Fu, Y., Xie, Y., Zhang, X., Li, W., Peng, B., Jing, Y., Hu, J., Li, Q., Zhang, Y., & Yang, S. (2026). Cost-effectiveness of new guideline-based management for primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System, 27. https://doi.org/10.1177/14703203261505146

Vancouver

Fu Y, Xie Y, Zhang X, Li W, Peng B, Jing Y, et al. Cost-effectiveness of new guideline-based management for primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System. 2026;27. doi:10.1177/14703203261505146

BibTeX
@article{Fu2026,
  author = {Fu, Yiyang and Xie, Yongpeng and Zhang, Xizi and Li, Wei and Peng, Bin and Jing, Ying and Hu, Jinbo and Li, Qifu and Zhang, Yao and Yang, Shumin},
  title = {Cost-effectiveness of new guideline-based management for primary aldosteronism},
  journal = {Journal of the Renin-Angiotensin-Aldosterone System},
  year = {2026},
  volume = {27},
  doi = {10.1177/14703203261505146}
}
Kostenlos starten →